FDA Warning Streak Continues, Underscoring Risky Products And Claims
This article was originally published in The Rose Sheet
Executive Summary
Agency has been turning up the heat this summer on skin-care marketers, posting two more July warning letters issued to companies for use of unapproved drug claims. Firms that sell anti-aging serums, eye-area formulas or anything promoted as an “anti-wrinkle” solution should review their claims to ensure compliance.